Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of pilocarpine hydrochloride ophthalmic solution for adult presbyopia
CTR20244733Phase 3Completed
- Sponsor
- Beijing Fuyuan Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in presbyopia comparing Pilocarpine hydrochloride ophthalmic solution with Placebo ophthalmic solution (2 arms). Primary endpoint: Responder rate for binocular DCNVA improvement at 3 hours post-dose without meaningful CDVA loss. Started Dec 2024; status: completed.
02
Drugs
pilocarpine
03
Conditions
presbyopia
Beyond the preview
Go deeper on CTR20244733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244733.